Sandoz’ antiinfectives partner Ares...Just in mid-December, antibiotic resistance detection expert Ares Genetics (Vienna, Austria) inked an agreement with Sandoz to use its pathogenome database and bio-IT know-how to develop repurposed … more ➔
AI provides face read-out of genetic disea...Experts in artificial intelligence (AI) have created another problem for bioethicists and data protection specialists: their algorithm has learned to identify people with rare genetic syndromes from … more ➔
Sanofi ends immuno-oncology discovery with...Sanofi and Regeneron announced they have "restructured" their US$2,17bn immunoncology collaboration. While the companies will continue co-marketing of the FDA approved (2018) PD1 blocker cemiplimab … more ➔
Diverse cells make up the endotheliumCells that line the blood vessels do not behave identically but instead exhibit varied responses to the same biochemical signals, British researchers report in Science. more ➔
Microbiome defines gut conditionsDifferences in microbiome composition can help to distinguish inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Dutch and US researchers report. more ➔
Cellestia Biotech AG attracts Series A fin...Cancer specialist Cellestia Biotech AG has secured CHF20m through a Series A financing led by FC Capital, and PPF / Sotio, and ETP Ventures, Boston & Beijing. more ➔
Staten Biotechnology in $430m deal with No...Staten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk. more ➔
Kurma Partners announce closing of Biofund...Paris-based Kurma Partners announced the first closing of its Kurma Biofund III, a life science fund set to raise €150m. more ➔
MEPs back €120bn budget for Horizon Euro...The European Parliament has voted to add €36.5bn to the budget of Horizon Europe (€94.1bn, in 2018 prices) proposed by the European Commission to foster research and innovation. more ➔
New cheap CRS-blockers at the horizonCancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed with IL-6R-blockers. US oncologists now report that an FDA-approved hypertension drug did the … more ➔
